APEIRON Biologics AG

Founded

2003

Staff

45

Organization type

RDM biotech/pharma

Region

Vienna

Apeiron Biologics AG is a private immuno-oncology focused company. A monoclonal antibody (mAb, Dinutuximab beta) for immunotherapy of high-risk neuroblastoma has successfully been brought to market (EMA approval in May 2017). The product was licensed out to EUSA Pharma. Apeiron’s APN401 project is 1st in class autologous cellular therapy to strengthen immune reactivity via an intracellular master check point cbl-b. A series of low molecular weight compounds (preclinical) are being developed.

R&D:Apeiron has a dual development strategy: mAb projects in clinical stage (APN301, an immune-cytokine; APN11 dinutuximab beta - already marketed) selectively targeting tumors expressing GD2 - both in orphan and larger tumor indications, as well as unique, novel checkpoint inhibition series - applicable to solid and hematopoietic tumors.